Tag Archive for: T-cell engager

resource-database-GWktL2yRXtA-unsplash
Venture Capital

Cytospire raises £61M to take gamma-delta T-cell engager into the clinic

Cytospire Therapeutics has raised a £61 million (€71 million) Series A round, positioning the British biotech to advance pan-gamma-delta T-cell engagers (TCEs) into cancer clinical trials.

Read more
UCB Candid Bio acquisition
M&A

UCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager push

Belgian biopharma UCB has moved quickly from testing the waters in autoimmune T-cell engagers to making one of the largest bets yet on the modality, agreeing to acquire San Diego-based Candid Therapeutics for up to US$2.2bn.

Read more
joanna-kosinska-VYEX2RnI1uA-unsplashPicture by Joanna Kosinska via Unsplash
Licencing

Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics

Sanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics’ next-generation tri-specific T-cell engager targeting B cell-mediated autoimmune diseases.

Read more